The clinics and the research laboratories of the Waisman Center intertwine to care for individuals with cerebral palsy. The mission is one: to improve the outcomes for individuals with cerebral palsy.
Year: 2023
Resilience doesn’t equate to positive outcomes for individuals who have experienced early childhood maltreatment
Early childhood maltreatment can have long lasting effects that follow a person into adulthood.
Alexander disease: A lifetime’s work in the hope of saving lives
Messing wanted to study if the overexpression of GFAP resulted in a certain reactive response in the brain.
New machine learning tool helps researchers demonstrate effectiveness of stem cell based models
Today, many researchers are using brain organoids – miniaturized and simplified versions of organs produced in a dish typically from stem cells – as analogs for studying the development of the human brain.
Jenny Saffran, PhD – Slide of the Week
Online data collection methods pose unique challenges and opportunities for infant researchers.
Ruth Litovsky featured on “Conversation with a Colleague”
Luigi Puglielli, MD, PhD – Slide of the Week
N ε-lysine acetylation within the lumen of the endoplasmic reticulum is a recently characterized protein quality control system that positively selects properly folded glycoproteins in the early secretory pathway.
A college degree may protect against neurodegeneration in genetically at-risk populations
Obtaining a college degree may be protective against neurodegenerative symptoms in women with an elevated genetic risk.
David Gamm works to bring research and medicine into a single vision
David Gamm is adept at keeping multiple things in focus. Gamm, MD, PhD, is a Waisman investigator, director of the McPherson Eye Research Institute, and professor of ophthalmology and visual sciences. With one eye trained on patients, he treats children in the pediatric ophthalmology clinic.
Robert A. Pearce, MD, PhD – Slide of the Week
We recently reported that the competitive NMDAR antagonist (R,S)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP) does not suppress NMDAR-mediated field EPSPs (fEPSPNMDA) or long-term potentiation (LTP) in vitro at concentrations that block contextual conditioning in vivo. Here we tested one possible explanation for the mismatch – that the hippocampus is relatively resistant to CPP compared to other brain structures engaged in contextual fear conditioning.